Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

In Silico Studies of Novel Vemurafenib Derivatives as BRAF Kinase Inhibitors.

Molecules (Basel, Switzerland) - 7 Jul 2023

Żołek Teresa, Mazurek Adam, Grudzinski Ireneusz P

Abstract excerpt

BRAF inhibitors have improved the treatment of advanced or metastatic melanoma in patients that harbor a BRAFT1799A mutation. Because of new insights into the role of aberrant glycosylation in drug resistance, we designed and studied three novel vemurafenib derivatives possessing pentose-associated aliphatic ligands-methyl-, ethyl-, and isopropyl-ketopentose moieties-as potent BRAFV600E kinase inhibitors. The...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Neoplasm
Share to Indoles
Share to Ligands

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Melanoma

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Share to Sulfonamides

Share to Vemurafenib

Source

Open in PubMed Open full text

Identifiers

PMID: 37446932
DOI: 10.3390/molecules28135273
PMCID: PMC10343629

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

In Silico Studies of Novel Vemurafenib Derivatives as BRAF Kinase Inhibitors.PMID 37446932Read ↗

Vemurafenib.Semantic proximity Read ↗

Pyrimidin-4-bromobenzenesulfonamide/-4-nitrobenzenesulfonamide hybrids as potential BRAFV600E inhibitors: experimental, computational and biological evaluations.Semantic proximity Read ↗

Vemurafenib for the treatment of BRAF mutant metastatic melanoma.Semantic proximity Read ↗

In silico evaluation of selected triterpenes as potential inhibitors of BRAF and BRAFV600E kinases for cancer treatment.Semantic proximity Read ↗

Targeted design, synthesis, molecular simulation, ADME-T and in-vitro anticancer assessment of phenyl-substituted-thioxo-tetrahydro-pyrimidin-benzenesulfonamide derivatives as potential BRAFV600E/WT inhibitors.Semantic proximity Read ↗

Identification of type II inhibitors targeting BRAF using privileged pharmacophores.Semantic proximity Read ↗

Design, Synthesis and In Vitro Analysis of New Vemurafenib AnalogsSemantic proximity Read ↗

Vemurafenib: the first drug approved for BRAF-mutant cancer.Semantic proximity Read ↗

Insights into the structure-activity relationship of pyrimidine-sulfonamide analogues for targeting BRAF V600E protein.Semantic proximity Read ↗

Synthesis, biological evaluation and molecular docking of novel 5-phenyl-1H-pyrazol derivatives as potential BRAF(V600E) inhibitors.Semantic proximity Read ↗

Computational investigation of imidazo[2,1-b]oxazole derivatives as potential mutant BRAF kinase inhibitors: 3D-QSAR, molecular docking, molecular dynamics simulation, and ADMETox studies.Semantic proximity Read ↗

Vemurafenib in Chinese patients with BRAFV600 mutation-positive unresectable or metastatic melanoma: an open-label, multicenter phase I study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.